Journal of the Japan Society of Blood Transfusion
Online ISSN : 1883-8383
Print ISSN : 0546-1448
ISSN-L : 0546-1448
Search
Advanced search
OR
Browse
Search
Volume 35, Issue 4
Displaying 1-9 of 9 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
  • EFFECTS OF PLASMA pH AND BLOOD GASES ON PLATELET CONCENTRATE
    Yoshihida Ishikawa, Shigeru Sasakawa
    1989 Volume 35 Issue 4 Pages 415-418
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.415
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The effects of pH, PCO2 in plasma on platelet concentrate (PC) were examined. For obtaining PCs with different pH and gas pressures, concentration of platelet, PC volume and bag size were altered and the PCs were stored for 72-120 hours in polyvinyl chrolide bags. PCO2 increased and PO2 decreased by lowering pH. PC in lower than pH 6, however, exibited the gas pressures as same as PC with pH higher than about 7.2. Mean platelet volume (MPV) increased by decreasing pH. MPV of PC in lower than pH 6 was about 1.5 times that with neutral pH. The effects of pH on platelet functions were also examined using fresh platelet rich plasma whose pH was changed with HCl or NaOH. After 24 hours-storage, ADP- and collagen-induced aggregation decreased by increasing pH. MPV, shape change ability and %HSR were mainteined well in PC with pH around neutrality. These results suggest that the measurement of pH is useful for quality control of PC and suggest that PCO2, PO2 can be estimated from pH. It is considered to be preferable that PC is stored with pH from 6.6 to 7.4.
    View full abstract
    Download PDF (419K)
  • The Clinical Significance of Anti-Bga-51Chromium Survival Studies
    P. M. Azar, S. Ogawa, T. Yasuda, S. Yahara, H. Saji, T. Hosoi, H. Fuji ...
    1989 Volume 35 Issue 4 Pages 419-423
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.419
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    An attempt to determine the clinical significance of anti-Bga was performed by transfusing 51Cr-labelled red blood cells (RBC) from HLA-B7 positive donors to four patients who had histories of anti-Bga. Pre- and post-transfusion samples showed no change in antibody titer scores, haptoglobin or complement levels. Three of the patients were then transfused with 51Cr-labelled RBC from HLA-B7 negative donors and the half-life (T50Cr) of both were compared. Although low, the T50Cr of HLA-B7 incompatible RBC appeared to be similar to the T50Cr of HLA-B7 compatible RBC.
    View full abstract
    Download PDF (568K)
  • PRODUCTION OF MONOCLONAL ANTI-D FOR USE IN TYPING BLOOD GROUPS
    Hajime Yamano, Hideo Takahashi, Toru Nakade, Yasuto Okubo, Hideo Yamag ...
    1989 Volume 35 Issue 4 Pages 424-433
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.424
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A monoclonal anti-D typing reagent was prepared in following ways.
    The monoclonal anti-D was generated in hybridoma cell line (DBF-11) established by the use of “EBV-Hybridoma Technique”, in which an Epstein-Barr Virus (EBV)-transformed monoclonal anti-D (IgG1, κ chain) producing human B-cell line (B2-1) was fused with non-immunoglobulin producing JMS-3 cell.
    Mass culture of the cell line (DBF-11) was continued for the period of over 131 days, by using the continuous cell culturing apparatus (Bio-Pro) provided with “vitafiber”.
    Weight of the monoclonal anti-D obtained from 8.17 liters of the cultured supernatant fluid was 5.1g expressed in terms of human IgG.
    After being roughly purified with “hollowfiber”, the IgG content was 4.4g.
    The Fc portion of the roughly purified IgG (40μg/ml) was bound with mouse anti-human IgG (Fc monospecific antibody: 32μg/ml) so that the monoclonal anti-D was rendered suitable for a blood typing reagent.
    View full abstract
    Download PDF (2700K)
  • A CROSS-REACTIVE ANTIBODY AGAINST Bga(+) RED BLOOD CELLS AND HLA-B7(+) LYMPHOCYTES
    Fumio Komatsu, Manabu Shikata
    1989 Volume 35 Issue 4 Pages 434-437
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.434
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A woman with fourth pregnancy produced an antibody which reacted with Bga(+) red blood cells, HLA-B7(+) lymphocytes and the lymphocytes of her husband and their new bady (cord cells). Her husband and the baby, however, showed Bga negative. The finding invited further determination of HLA type of them. Her husband and the baby demonstrated HLA-Bw 61 positive on lymphocytes, but she did not. After her serum was absorbed with HLA-B7(+) platelets, the reactivity against Bga red cells, HLA-B7 lymphocytes and the lymphocytes of her husband and the baby in the serum disappeared. These results suggest that this woman was sensitized with HLA-Bw61(+) lymphocytes of her husband and produced anti-HLA-Bw61 antibody, and that the antibody exhibited cross-reactive against Bga red cells and HLA-B7 lympyhocytes. A cross-reactivity among HLA-B7 and HLA-Bw61 was has been noticed. It is very interesting that anti-HLA-Bw61 may have cross reaction with Bga red cells.
    View full abstract
    Download PDF (490K)
  • A CASE OF HBV CARRIER AFTER ACCIDENTAL EXPOSURE TO HBV IN ADULTHOOD
    Masanobu Nohara, Akemi Tanaka, Kazuya Zeki, Hisahiro Sakamoto
    1989 Volume 35 Issue 4 Pages 438-443
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.438
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A case of HBV carrier after accidental exposure to HBV in adulthood was reported. This case is a 23-years-old nurse, and the HBV carrier state has persisted for more than fifteen months after accidental exposure to HBV. In this period of time, the levels of serum transaminase were raised to a slight degree than normal range. Nevertheless the levels of LDH, TTT and ZTT has remained within normal range.
    In addition, subpopulation and subset of peripheral T or B lymphocyte in the immunological examinations were completely normal. But in the specific cell proliferative response to the purified HBs antigen was decreased in this case.
    View full abstract
    Download PDF (670K)
  • LEUKAPHERESIS IN 2 CASES OF HYPERLEUKOCYTIC ACUTE LEUKEMIA
    Yoshio Saburi, Tsuyoshi Inage, Miki Yakushinzi, Toshiyuki Nakayama, Ta ...
    1989 Volume 35 Issue 4 Pages 444-449
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.444
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    We performed leukapheresis in combination with chemotherapy in 2 cases of acute leukemia in which the white blood cell count showed greater than 300, 000/μl.
    As a result of this treatment, a case (AMOL) achieved complete remission in spite of the complication of cerebral bleeding, but the other case (AML) failed to achieve complete remission due to severe cerebral thrombosis. As one of the reasons for complete remission, we think that the leukapheresis had inhibited the progression of cerebral bleeding before chemotherapy became effective. The white blood cell count decreased promptly after the administration of chemotherapy in both cases. From these cases, we suggest that the combination of leukapheresis and chemotherapy is useful for severe hyperleukocytic acute leukemia.
    View full abstract
    Download PDF (5135K)
  • HEMOPOIETIC REGULATION ASSESSED IN CLONAL CULTURE: A BRIEF OVERVIEW
    Makio Ogawa, Yoshihiro Fujimori
    1989 Volume 35 Issue 4 Pages 450-454
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.450
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The central feature of hemopoiesis is the life-long, stable cell renewal. This process is supported by homopoietic stem cells which, in the steady-state, appear to be dormant in cell cycling. The entry into cell cycle of the dormant stem cells may be promoted by such factors as IL-6 and G-CSF. The reported effect of IL-1 on stem cells appears to be indirect, mediated in part by IL-6 and G-CSF. Once the stem cells leave the G0 and begin proliferation, the subsequent process is characterized by steady proliferation and differentiation. The proliferation of early hemopoietic progenitors appears to be supported by IL-3, GM-CSF and/or IL-4. Micromanipulation studies of individual progenitors suggest that the commitment of multipotential progenitors to single lineage is a stochastic (random) process. Once the progenitors are committed to individual lineages, the subsequent proliferation and maturation appear to be supported by lateacting, lineage-specific factors such as Ep, M-CSF, G-CSF and IL-5. Thus, the hemoietic proliferation is regulated by a cascade of factors directed at different developmental stages.
    View full abstract
    Download PDF (733K)
  • Plasma Products for Hemophilia Treatment
    Carol K. Kasper
    1989 Volume 35 Issue 4 Pages 455-461
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.455
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    A wide variety of plasma products are available for hemophilia treatment, and new ones soon will be introduced. Major safety concerns are reduction of transmission of viruses and, for factor IX (FIX) complex concentrates, reduction of thrombogenicity. Viral transmission can be reduced by use of cryoprecipitate prepared from repeatedly-pheresed dedicated donors; by separation of viruses in concentrate production by increased purification; and by inactivation of viruses by such methods as heat, or dissolving the lipid envelopes of certain viruses with solvent-detergent combinations, or ultraviolet irradiation in conjuction with use of an alkylating agent or, experimentally, a photosensitizing agent. Factor VIII (FVIII) concentrates made by recombinant DNA technology in cell culture are in clinical trials. Thrombogenicity of FIX concentrates can be reduced by removing prothrombin and factors VII and X. We hope to improve or maintain safety, reasonable prices, and adequate supplies.
    View full abstract
    Download PDF (1210K)
  • Reports
    The report of the committee for appropriation of blood transfusion
    1989 Volume 35 Issue 4 Pages 477-490
    Published: October 01, 1989
    Released on J-STAGE: March 12, 2010
    DOIhttps://doi.org/10.3925/jjtc1958.35.477
    JOURNAL FREE ACCESS
    Download PDF (1681K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top